聚乙二醇化重组人粒细胞刺激因子在造血干细胞移植后促进造血恢复的疗效分析

来源期刊：广州医药 | 56-60 发布时间：2022-11-30 收稿时间：2025/11/13 18:14:48 阅读量：68

作者：: 张晓瀚,

陈诗彧,

汪鹏程,

蔡云,

杜新,

关键词：: 聚乙二醇化重组人粒细胞刺激因子造血干细胞移植重组人粒细胞刺激因子造血恢复; PEG-rhG-CSF hematopoietic stem cell transplantation rhG-CSF hematopoiesis recovery

DOI：: 10.3969/j.issn.1000-8535.2022.06.012

收稿时间：: 2021-10-20
修订日期：
接收日期：
引用总数：: 1

目的观察聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)与重组人粒细胞刺激因子(rhG-CSF)在造血干细胞移植后促进造血恢复的疗效对比。方法回顾分析2016年1月—2020年12月以来在深圳市第二人民医院血液科进行造血干细胞移植的恶性血液疾病患者共 100例,随机分为2组,分别在造血干细胞回输后给与聚乙二醇化重组人粒细胞刺激因子与重组人粒细胞刺激因子。结果 PEG-rhG-CSF组与rhG-CSF组中性粒细胞植入时间分别为(18.7±3.4)天、(18.0±3.1)天,P=0.281,无统计学差异。粒细胞缺乏伴发热在PEG-rhG-CSF组与rhG-CSF组分别发生26例、29例,发生率分别为53.06%、56.86%,P=0.89,无差异。用药次数分别为2.6次(2~5次)、18.1次(11~31次),P<0.05,差异有统计学意义。不良反应主要为骨痛、肌肉疼痛。结论 PEG-rhG-CSF组与rhG-CSF组结果相似,PEG-rhG-CSF具有用药次数少的优势。

1、 WEYCKER D,BENSINK M,LONSHTEYN A,et al.Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment[J].Curr Med Res Opin,2019,35(6):1073-1080.

2、 FONTAINE C,CLAES N,GRAAS M P,et al.Effect of lipegfilgrastim administration as prophylaxis of chemotherapy-induced neutropenia on dose modification and incidence of neutropenic events: real-world evidence from a non-interventional study in Belgium and Luxembourg[J].Acta Clin Belg,2021,76(1):10-15.

3、 TIMMER-BONTE J,OUWERKERK J,FABER L M,et al.Lipegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in Dutch patients[J].Neth J Med,2020,78(5):270-276.

4、范志松,邢栋,董志杰,等.粒细胞集落刺激因子引发骨痛的机制及其治疗的研究进展[J].中国新药与临床杂志.2020,39(7):390-393.

5、张永娜,贺宝霞,张振鑫,等.短效与长效粒细胞刺激因子用于恶性肿瘤化疗所致骨髓抑制的疗效及成本-效果分析[J].中国医院药学杂志,2020,40(20):59-63.

6、刘凯奇,王迎,赵姿,等.初诊急性髓系白血病诱导治疗后聚乙二醇化重组人G-CSF与普通重组人G-CSF促进中性粒细胞恢复的单中心随机对照研究 [J].中华血液学杂志,2019,40 (6): 497-501.

7、马军,朱军,徐兵河,等.聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)临床应用中国专家共识[J].中国肿瘤临床,2016,43(7):271-274.

8、 GERDS A,FOX-GEIMAN M,DAWRAVOO K,et al.Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation[J].Biol Blood Marrow Transplant,2010,16(5):678-685.

9、张春云,邵杰,吴雅丽,等.聚乙二醇化重组人粒细胞集落刺激因子注射液在健康志愿者中的药动学和药效学研究[J].现代药物与临床,2017,32(9):1614-1619.

10、 YANG B B,KIDO A .Pharmacokinetics and pharmacodynamics of pegfilgrastim[J].Clin Pharmacokinet,2011,50(5):295-306.

11、李晓燕,潘莹,魏雪,等.聚乙二醇化重组人粒细胞刺激因子致白细胞增多的国内外文献分析[J].中国医院药学杂志,2018,38(24):2580-2583.

12、徐兵河,宋艳秋,王京芬,等.聚乙二醇化重组人粒细胞刺激因子预防化疗后中性粒细胞减少的多中心随机对照Ⅱ期临床研究[J].中国肿瘤临床与康复,2016,23(1):3-7.

13、 BISHOP M R,TARANTOLO S R,GELLER R B,et al.A randomized,double-blind trial of filgrastim(granulocyte colony-stimulating factor)versus placebo following allogeneic blood stem cell transplantation[J].Blood,2000,96(1):80-85.

14、 BATTIWALLA M,MCCARTHY P L.Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice[J].Bone Marrow Transplant,2009,43(5):351-356.

15、 VANSTRAELEN G,FRRE P,NGIRABACU M C,et al.Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation[J].Exp Hematol,2006,34(3):382-388.

16、 QIN Y,HAN X,WANG L,et al.A phase I study of different doses and frequencies of pegylated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF) in patients with standard-dose chemotherapy-induced neutropenia[J].Chin J Cancer Res,2017,29(5):402-410.

17、 KUBO K,MIYAZAKI Y,MURAYAMA T,et al.A randomized,double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R)chemotherapy for malignant lymphoma[J].Br J Haematol,2016,174(4):563-570.

18、 WEAVER C H,SCHWARTZBERG L S,HAINSWORTH J,et al.Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers[J].Bone Marrow Transplant,1997,19(7):671-678.

1、李琳慧,杨月梅,田劲猛.关于PEG-rhG-CSF在预防结直肠癌化疗中性粒细胞减少的对比研究[J].云南医药,2023,44(06):44-46.DOI:10.20282/j.cnki.1006-4141.2023.06.013.